Veru INC 8-K filings

NASDAQ

15 Feb 2024

VERU

8-K: Veru Inc. to Restate Financials Due to R&D Expense Overestimation

Veru Inc. announced it will restate prior financial statements due to errors in overestimating research and development expenses, which impacts the company's cash runway.

NASDAQ

8 Feb 2024

VERU

Veru INC

8-K: Veru Inc. Announces Positive Clinical Trial Progress and Financial Update

Veru Inc. reports FDA clearance for enobosarm obesity study, plans Phase 2b trial, and provides financial highlights for the first fiscal quarter of 2024.

NASDAQ

26 Jan 2024

VERU

Veru INC

8-K: Veru Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Rule

Veru Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has been below $1.00 for 30 consecutive business days.